List view / Grid view
As part of our series highlighting women in STEM, we spoke to Juliet Williams, Head of Research at Kymera. She discusses what inspired her early passion for science, the power of mentorship and what excites her most about the future of targeted protein degradation – and its potential to deliver…
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
